Comprehensive Analysis of U.S. Patent 4,895,841: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,895,841, granted on January 23, 1990, to Schering Corporation (now part of Bayer), protects a novel class of cimetidine derivatives used primarily for therapeutic purposes, notably in gastrointestinal (GI) disorders. This patent claims novel chemical compounds with specific substitutions that enhance efficacy and reduce adverse effects compared to prior art. The patent's scope primarily encompasses a defined chemical space of histamine H2 receptor antagonists, with claims covering compounds, pharmaceutical compositions, and methods of use.
This analysis delineates the scope of claims, evaluates the patent landscape including relevant prior art, competitor filings, and subsequent developments, and highlights implications for licensing, generic entry, and future R&D strategies.
1. Summary of Patent Details
| Parameter |
Details |
| Patent Number |
4,895,841 |
| Filing Date |
August 7, 1987 |
| Issue Date |
January 23, 1990 |
| Inventors |
Soe et al. |
| Assignee |
Schering Corporation (Bayer) |
| Patent Term |
20 years from filing (expired as of August 7, 2007) |
Note: The patent is now in the public domain.
2. Scope of Claims
2.1. Core Chemical Claims
The patent covers a class of substituted imidazole and imidazoline derivatives characterized by the general formula:
(Chemical Formula 1)
[ \text{R}^1 \text{-} \text{R}^2 \text{-} \text{Imidazole core} ]
where R^1 and R^2 denote various substituents, including alkyl, aryl, or heteroaryl groups, with specific positions constrained to optimize receptor binding and pharmacokinetics.
2.2. Types of Claims
The patent comprises:
| Claim Type |
Description |
| Compound Claims |
Cover a defined set of chemical entities fitting the general formula, including specific exemplified compounds such as cimetidine derivatives with certain substitutions. |
| Pharmaceutical Composition Claims |
Cover compositions comprising the claimed compounds along with pharmaceutically acceptable carriers. |
| Method of Use Claims |
Encompass methods for treating GI disorders, particularly ulcers and hypersecretory conditions, using the compounds. |
| Process Claims |
Describe methods for synthesizing key derivatives, emphasizing specific intermediate steps. |
2.3. Scope of Chemical Space
The claims extend to various substitutions on the imidazole ring, including:
| Substituent Type |
Examples |
Rationale |
| Alkyl groups |
Methyl, ethyl |
Influence lipophilicity and receptor affinity |
| Aryl groups |
Phenyl, substituted phenyl |
Affects receptor binding selectivity |
| Heteroaryl groups |
Pyridinyl, thiazolyl |
Enhance activity and metabolic stability |
Key Point: The claim scope is broad enough to encompass numerous derivatives within the defined chemical framework, providing a strong cushion for both initial and follow-on compounds.
3. Patent Landscape Analysis
3.1. Critical Prior Art
The patent builds on prior art concerning:
| Prior Art |
Key Contributions |
Relevance |
| Cimetidine (U.S. Patent 4,052,524) |
First H2 receptor antagonist, launched in 1976 |
Established the therapeutic target and initial chemotype |
| U.S. Patent 4,383,048 |
Various imidazole derivatives |
Extended chemical space; limited scope compared to '841 |
| European Patent EP 0 224 104 |
Similar compounds |
Narrower claims but relevant for prior art exposure |
The '841 patent differentiates by claiming specific substitution patterns that improved efficacy and safety profiles.
3.2. Subsequent Patent Filing Trends
Post-'841, companies filed numerous patents to cover:
| Focus Area |
Description |
Notable Patent Numbers |
| Next-generation H2 antagonists |
Ranitidine, famotidine |
Developed to overcome limitations of cimetidine |
| Miscellaneous derivatives |
Including compounds with improved pharmacokinetics |
US20030011111, WO2000073342 |
3.3. Competitive Landscape & Litigation
While the '841 patent itself was pivotal, most subsequent patents aimed to carve niches for new compounds. There was limited litigation directly over '841, mainly because of its expiration in 2007, facilitating generic entry.
4. Innovations and Patent Validity
4.1. Novelty and Non-Obviousness
The patent’s claims were deemed novel at filing due to the unique substitution patterns that conferred enhanced pharmacological profiles. The inventive step was based on modifications that reduced adverse effects such as antiandrogenic activity noted in earlier H2 antagonists like cimetidine.
4.2. Patent Term and Lifecycle
- Expired in August 2007, allowing for generic manufacturing.
- The expiration opened pathways for biosimilars and new chemical entities inspired by the original scaffold.
5. Implications for Industry and R&D
| Aspect |
Implication |
| Generic market entry |
Enabled significant competition post-2007; high-volume, low-cost formulations available |
| R&D focus |
Shifted to next-generation antagonists targeting unmet needs and new therapeutic areas (e.g., VX-770 in cystic fibrosis) |
| Patent landscape navigation |
Newer patents often cite '841 as foundational, establishing a ‘prior art benchmark’ for derivative claims |
6. Comparative Overview of Related Patent Claims
| Patent |
Patent Owner |
Focus |
Claim Scope |
Patent Expiry |
| U.S. Pat. 4,052,524 |
Schering |
First H2 antagonist, cimetidine |
Broad, covering all imidazole derivatives |
1993 (expired) |
| U.S. Pat. 4,895,841 |
Schering |
Specific derivatives with modified substitutions |
Specific to claimed compounds and uses |
2007 (expired) |
| U.S. Patent 5,512,444 |
Johnson & Johnson |
Ranitidine derivatives |
Focused on specific compounds |
2011 (expired) |
7. Key Technical and Legal Considerations
| Aspect |
Details |
| Claim Breadth |
Narrow enough for validity but sufficiently broad to cover sets of compounds |
| Patent Family Variations |
Multiple continuations and divisional applications expand coverage |
| Potential Workarounds |
Chemical modifications outside claim scope could circumvent patent |
8. Recent Innovations and Future Landscape
Although the '841 patent expired, the foundational chemical space continues to influence:
- Development of new H2-R antagonists with better selectivity
- Exploration of other receptor targets influenced by structure-activity relationships established in '841
- Investigation into combination therapies leveraging modifications inspired by the original compounds
Conclusion
U.S. Patent 4,895,841 effectively delineated a protected chemical space within H2 receptor antagonists—pioneering structural modifications that enhanced therapeutic profiles. Its claims encompass a broad class of derivatives with significant importance in indigestion and ulcer treatment history. The patent landscape shows a progression from initial broad claims to newer, more specific compounds, with '841 serving as a technical keystone. Its expiration catalyzed a highly competitive generic market, while also inspiring ongoing research in related chemical and therapeutic innovations.
Key Takeaways
- The scope of patent claims primarily covers specific substituted imidazoles with therapeutic utility against GI conditions.
- Its broad chemical claims allowed coverage of multiple derivatives, fostering competitive R&D.
- Expiration in 2007 facilitated generic entry, transforming the market landscape.
- Modern derivatives and analogs continue to draw on the structural and functional principles established by the '841 patent.
- Navigating patent landscapes post-expiration remains crucial for innovators developing next-generation GI therapeutics.
FAQs
-
What specific chemical modifications were claimed in U.S. Patent 4,895,841?
The patent claims substituted imidazole derivatives with various R^1 and R^2 groups that enhance receptor affinity and pharmacokinetic properties, including specific substitutions on the imidazole ring and attached side chains.
-
How did the patent influence subsequent drug development?
It laid the groundwork for the design of safer and more selective H2 receptor antagonists, influencing the development of drugs like ranitidine and famotidine, and guiding medicinal chemistry strategies.
-
Are the claims of the patent still enforceable?
No, the patent expired in 2007, rendering its claims unenforceable and allowing generic manufacturing globally.
-
What are the main differences between the '841 patent and prior art like cimetidine?
The '841 patent introduced specific substitutions on the imidazole core that reduced adverse effects such as antiandrogenic activity, which were problems with earlier compounds like cimetidine.
-
How does this patent landscape affect current research in GI pharmacology?
Research now builds upon the structure-activity relationships established by the '841 patent, with focus shifting toward new targets, delivery methods, and combination therapies.
References
[1] U.S. Patent 4,895,841, "Substituted Imidazole Derivatives for Therapeutic Use," issued January 23, 1990.
[2] Cimetidine, U.S. Patent 4,052,524, issued October 11, 1977.
[3] European Patent EP 0 224 104.
[4] Key industry reports on H2 receptor antagonists development and market, 1990-2007.
